Document is current

Article History

Received: 10 May 2023

Accepted: 6 August 2024

First Online: 6 September 2024

Declarations

:

: The study was performed according to regulations of the local ethics committee. Informed consent was obtained from each patient before enrolment. Data were extracted and anonymized by using a numerical identifier.

: Not applicable.

: LGD has received fees as scientific advisor or participant in clinical studies from (in alphabetical order): Akcea, Alnylam, Astrazeneca, Pfizer and Sobi. FMV has received fees as scientific advisor or participant in clinical studies from (in alphabetical order): Alnylam, Akcea and Pfizer. JBR has no conflict of interest to declare. JGM has received fees as scientific advisor or participant in clinical studies from (in alphabetical order): Alnylam, Akcea and Pfizer. ILL has received fees as scientific advisor or participant in clinical studies from (in alphabetical order): Alnylam, Akcea and Pfizer. TS has received fees as scientific advisor or participant in clinical studies from (in alphabetical order): Alnylam, Akcea and Pfizer. FMB has received fees as scientific advisor or participant in clinical studies from (in alphabetical order): Akcea, Alnylam, Pfizer and Sobi. JEBL has no conflict of interest to declare. MRA has received fees as scientific advisor or participant in clinical studies from (in alphabetical order): Alnylam and Pfizer. FS is a full-time employee of Pfizer SLU and holds stock and stock options in Pfizer Inc. DP is a full-time employee of Pfizer SLU. PT is a full-time employee of Pfizer SLU and holds stock and stock options in Pfizer Inc.